Hantavirus: What It Is, How It Spreads, and the Risk Picture

**A family, not a virus.** "Hantavirus" is the name of a family of viruses (Hantaviridae, order Bunyavirales), not a single pathogen. Different hantaviruses are carried by different rodent species, occur in different geographic regions, and cause different patterns of human illness. Conflating them produces most of the confusion in non-specialist coverage. This section uses material from the World Health Organization, the United States Centers for Disease Control and Prevention, the European Centre for Disease Prevention and Control, the Pan American Health Organization, and the Belgian institute of public health (Sciensano).

**The discovery history.** The first hantavirus to be isolated and named was Hantaan virus, identified in 1978 by Korean and US researchers from rodents captured in the area of the Hantan river in South Korea. The virus had been the suspected cause of a recurrent severe febrile illness among troops during the Korean War a quarter-century earlier. Hantaan virus causes the disease pattern known as Haemorrhagic Fever with Renal Syndrome (HFRS) — fever followed by potential haemorrhagic features and kidney injury.

In the years following the Hantaan identification, related viruses with similar reservoir biology and similar clinical pictures were identified across Eurasia: Seoul virus (carried globally by *Rattus* rats), Puumala virus (carried by the bank vole, *Myodes glareolus*, in much of northern and western Europe including parts of Belgium), and Dobrava-Belgrade virus (carried by *Apodemus* mice in southeastern Europe). The HFRS family of diseases is the European and Asian face of hantavirus illness.

**The Four Corners outbreak.** In May 1993 a cluster of severe pulmonary illness in young, previously healthy adults emerged in the Four Corners region of the United States (where Arizona, New Mexico, Colorado, and Utah meet). Rapid investigation by the CDC, in cooperation with the Indian Health Service and local public-health authorities, identified a previously unknown hantavirus — eventually named Sin Nombre virus — carried by the deer mouse (*Peromyscus maniculatus*). The clinical syndrome was named Hantavirus Pulmonary Syndrome (HPS): fever progressing to severe respiratory distress, often requiring intensive care.

The Four Corners outbreak established that hantaviruses could cause a distinct, severe pulmonary syndrome — not just the renal-and-haemorrhagic pattern seen in Eurasia — and triggered ongoing surveillance of HPS in the Americas. Subsequent work has identified additional New World hantaviruses with pulmonary-syndrome associations: Andes virus in southern Argentina and Chile; Laguna Negra in Paraguay; Choclo in Panama; among others.

**Transmission: the standard route.** For essentially all hantaviruses, the standard transmission route to humans is inhalation of aerosolised excreta — urine, droppings, saliva — of infected rodents. The classical exposure scenario is a closed indoor space (a cabin, shed, attic, barn, or storage room) that has been long-inhabited by rodents and is then entered and disturbed, generating an aerosol of contaminated dust that the entrant inhales. Direct rodent bite is a rarer but documented route. The viruses are not transmitted by mosquitoes or other arthropod vectors.

**The Andes virus exception.** Andes virus, named for the Andes mountain range, is the one hantavirus for which person-to-person transmission has been documented in the medical literature. Investigations of clusters in southern Argentina and Chile — initially in 1996, and reinforced by subsequent clusters including a 2018–19 cluster in Argentine Patagonia — have established close-contact human-to-human transmission, including transmission to healthcare workers. The Andes-virus situation is the exception, not the rule, and remains a geographically constrained phenomenon. No other hantavirus has been confirmed to spread person-to-person under standard surveillance conditions.

**Clinical course and case-fatality.** The clinical course differs by viral species. For HPS in the Americas, case-fatality has been cited around 35–40 % historically — a very high figure — though this represents identified cases that reached medical attention severely enough to be diagnosed, and the true population case-fatality including milder unrecognised infections may be lower. For HFRS in Eurasia, case-fatality varies by virus: Hantaan virus historically around 5–15 %; Puumala virus generally below 1 %. Treatment is supportive — oxygen, fluid management, intensive-care support where needed. No antiviral has reached broad regulatory approval for hantavirus treatment.

**The vaccine landscape.** South Korea has used a Hantaan-virus vaccine in its national programme for decades — the only hantavirus vaccine in routine national use anywhere. No vaccine is currently licensed in the European Union or the United States. Vaccine development efforts for additional hantaviruses are at various preclinical and early-clinical stages internationally.

**Surveillance: who watches.** Hantavirus surveillance in Europe is coordinated through the European Surveillance System (TESSy), with annual epidemiological reports published by ECDC and country-level surveillance by national institutes of public health — Sciensano in Belgium, the Robert Koch Institute in Germany, Santé Publique France in France. In the United States the CDC publishes ongoing HPS surveillance data. In Latin America the Pan American Health Organization tracks HPS and Andes virus regionally.

**Hantavirus in Belgium.** Belgium has documented Puumala-virus infections over the years — the bank-vole reservoir is present in Belgian forests, particularly in the Ardennes and parts of Flanders. Annual case counts have been low (typically tens to low hundreds, with variation year-to-year tied to rodent population dynamics). Sciensano's surveillance bulletins are the authoritative Belgian source; clinical guidance follows European standard practice.

**The climate question.** A growing body of work examines how climate-driven changes in rodent populations may alter the distribution and frequency of hantavirus infections. Plausible mechanisms include shifts in the geographic range of reservoir species, changes in bank-vole and deer-mouse population cycles tied to acorn and seed masting, and altered patterns of human–rodent contact in warming regions. The work is active, and the magnitude of climate-attributable change is not yet quantified with confidence. Public-health agencies treat this as an area requiring ongoing surveillance rather than predicting specific outcomes.

**Pandemic risk: what the assessments actually say.** Public-health agencies maintain technical frameworks for assessing pandemic potential — including WHO's R&D Blueprint for priority pathogens and CDC's pandemic-influenza framework adapted to other pathogens. Hantaviruses are not currently on the WHO R&D Blueprint priority list. There is no public-health assessment placing hantaviruses in the same operational category as pandemic-potential respiratory pathogens such as influenza, coronaviruses, or paramyxoviruses with sustained person-to-person transmission.

This is a specific, technical statement — not a value judgement. The assessment can change if new data emerge: a hantavirus with documented sustained respiratory person-to-person transmission would change the picture sharply. As of the most recent agency assessments referenced in the *Sources* section, no such transmission has been documented for any hantavirus other than Andes (which is itself geographically constrained and does not show sustained chains of transmission outside its endemic region).

**Prevention: the practical baseline.** Public-health guidance is consistent across agencies: routine rodent-exclusion in homes, cabins, sheds, attics, and outbuildings is the most effective everyday preventive measure. When cleaning long-closed spaces that may have rodent infestation, the standard guidance is to ventilate first, avoid sweeping or vacuuming that generates aerosols, wet dust and droppings with a disinfectant solution before cleanup, and wear gloves and (where appropriate) a properly fitted respirator. Country-specific guidance from your national public-health institute (in Belgium: Sciensano; in France: Santé Publique France; in Germany: Robert Koch Institute) is the authoritative reference for your jurisdiction.

**Closing editorial note.** Health content on Belgium Impulse is editorially conservative by policy. We will not amplify pandemic-comparison framing unless the relevant public-health authorities publish such an assessment. We will report confirmed cases and clusters when reported by those authorities, with the dating and geographic scope they specify. For any personal medical concern, consult a qualified healthcare professional or contact your country's non-urgent medical service (in Belgium: 1733). This dossier is not medical advice.